First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03 janv. 2023 08h00 HE
|
Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Outlook on the Atrial Fibrillation Treatment Global Market to 2027 - Rising Prevalence of Cardiovascular Diseases Drives Growth
22 déc. 2022 06h38 HE
|
Research and Markets
Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Left Atrial Appendage Closure Devices Market worth USD 4.5 Billion by 2032, says Global Market Insights Inc.
21 nov. 2022 05h40 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The left atrial appendage closure devices market value is set to surpass USD 4.5 billion by 2032, according to a recent report by Global...
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
07 nov. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
04 oct. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...
S4 Medical Meets Primary Endpoint in Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF Study)
12 sept. 2022 07h30 HE
|
S4 Medical Corp
CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation...
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
31 août 2022 08h00 HE
|
Volta Medical
Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent...
Global Low Molecular Weight Heparin Market to Surpass US$ 6,539.3 Million by 2030, Says Coherent Market Insights (CMI)
22 août 2022 09h30 HE
|
CMI
Seattle, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global low molecular weight heparin market is estimated to be valued at US$ 3,903.1 million in 2022 and is...
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation
26 juil. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia...
Electrophysiology Market, a $15.7 billion Industry by 2030 with a CAGR of 10.8 %
05 juil. 2022 09h40 HE
|
STRATEGIC MARKET RESEARCH LLP
New York, United States, July 05, 2022 (GLOBE NEWSWIRE) -- The electrophysiology market in 2020 was worth USD 5.6 billion and, with a relatively high CAGR of 10.8%, is calculated to reach a value of...